Literature DB >> 2535852

Gonadotropin and alpha-subunit responses to chronic gonadotropin-releasing hormone analog administration in patients with glycoprotein hormone-secreting pituitary tumors.

A Klibanski1, J L Jameson, B M Biller, W F Crowley, N T Zervas, J Rivier, W W Vale, H Bikkal.   

Abstract

Pituitary tumors secreting intact glycoprotein hormones (LH, FSH, and TSH) and/or alpha-subunit are being increasingly recognized. Because chronic administration of GnRH analogs decreases gonadotropin secretion in normal subjects, we investigated gonadotropin and alpha-subunit responses to chronic GnRH analog administration in five men with glycoprotein hormone-secreting pituitary tumors. Two patients (patients A and B) received the GnRH agonist analog (D-Trp6-Pro9-NEt-LHRH) for 4 weeks as a daily sc dose (8 micrograms/kg.day). In both, secretion of LH and/or alpha-subunit increased markedly. Subsequently, three patients received a higher analog dose (32 micrograms/kg.day) for a longer duration (8 weeks). One patient with a LH- and FSH-secreting tumor (patient C) had a highly significant (P less than 0.001) fall in serum LH and FSH concentrations; however, alpha-subunit secretion increased. During a subsequent study, when this patient received a lower dose (8 micrograms/kg.day) for 8 weeks, gonadotropin suppression also occurred. In two additional patients who received this dose (32 micrograms/kg.day), it had a persistent agonist effect on FSH beta (patient D) and alpha-subunit secretion (patient E). A marked increase in alpha-subunit secretion occurred in all five patients, regardless of whether basal serum alpha-subunit concentrations were elevated. These patients received the GnRH analog at doses 2-8 times greater than those that suppress gonadotropin secretion in normal men. Serum LH and FSH concentrations decreased in only one patient with a gonadotropin-secreting adenoma. The serum LH and FSH responses to acute GnRH stimulation did not predict the gonadotropin responses to chronic GnRH analog administration. Thus, gonadotropin and alpha-subunit production by most pituitary adenomas is augmented during chronic GnRH analog administration, consistent with defective GnRH desensitization in the adenomatous tissue. Despite the heterogeneous gonadotropin responses to the GnRH analog in these patients, serum alpha-subunit levels increased in all patients, indicating dissociation in the secretion of intact gonadotropins and alpha-subunit.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2535852     DOI: 10.1210/jcem-68-1-81

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Medical therapy of gonadotropin-producing and nonfunctioning pituitary adenomas.

Authors:  Mansur E Shomali; Laurence Katznelson
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

2.  Detection of growth hormone, prolactin and human beta-chorionic gonadotropin messenger RNA in growth-hormone-secreting pituitary adenomas by in situ hybridization.

Authors:  H Uhlig; W Saeger; S Fehr; D K Lüdecke
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

3.  Pituitary apoplexy of a gonadotroph adenoma following gonadotrophin releasing hormone agonist therapy for prostatic cancer.

Authors:  Y Reznik; F Chapon; N Lahlou; N Deboucher; J Mahoudeau
Journal:  J Endocrinol Invest       Date:  1997-10       Impact factor: 4.256

Review 4.  Endocrine inactive and gonadotroph adenomas: diagnosis and management.

Authors:  M Losa; P Mortini; R Barzaghi; A Franzin; M Giovanelli
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

5.  Predominant suppression of follicle-stimulating hormone β-immunoreactivity after long-term treatment of intact and castrate adult male rats with the gonadotrophin-releasing hormone agonist deslorelin.

Authors:  A W Smith; C S Asa; B S Edwards; W J Murdoch; D C Skinner
Journal:  J Neuroendocrinol       Date:  2012-05       Impact factor: 3.627

Review 6.  Dopamine Agonists in the Management of Non-Functioning Pituitary Adenomas.

Authors:  C Capatina; C Poiana
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Jul-Sep       Impact factor: 0.877

7.  Gonadotropin-releasing hormone receptor mRNA expression by human pituitary tumors in vitro.

Authors:  J M Alexander; A Klibanski
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

8.  Responses to gonadotropin releasing hormone agonist and antagonist administration in patients with gonadotroph cell adenomas.

Authors:  P Chanson; N Lahlou; A Warnet; M Roger; G Sassolas; J Lubetzi; G Schaison; P Bouchard
Journal:  J Endocrinol Invest       Date:  1994-02       Impact factor: 4.256

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.